CV Sciences, Inc.: CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids

CV Sciences (OTCQB:CVSI) launched PlusHLTH.com, a direct-to-consumer site for its +PlusHLTH non-cannabinoid product line, expanding beyond its PlusCBDOil.com focus on hemp-derived CBD. The company says the site supports its “Health Intelligence” approach with science-backed education and plans to add new formulations and delivery formats.

Original reporting
Published Aug 12, 2026, 3:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 3:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CVSI
Bullish
medium confidence
Mentioned
$CVSI
Relevance
4/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CVSIBullishLow
01

Why it matters

The company is creating a dedicated DTC destination for +PlusHLTH while keeping PlusCBDOil.com focused on hemp-derived CBD, signaling continued brand expansion beyond cannabinoids.

02

Market read

This is a brand and channel expansion update. It may support sentiment around the company’s diversification strategy, but it lacks quantified financial impact.

03

What to watch

Traders may want to watch for follow-on disclosures such as new product SKUs, marketing spend changes, or any updates to distribution and compliance for non-cannabinoid supplements.

Relevance 4/10Novelty 4/10Timing: today’s PR, immediately following the PlusHLTH.com launch announcement

Background

CV Sciences is a consumer wellness company with the +PlusCBD brand and a newer +PlusHLTH line aimed at healthy aging and everyday health.

Company-level read

Ticker impact

$CVSIBullishMedium confidence
Context

CV Sciences announced the launch of PlusHLTH.com as the primary digital home for its +PlusHLTH non-cannabinoid product line.

Expected impact

Near-term impact likely limited to sentiment, with follow-through depending on subsequent sales/traffic metrics.

Evidence & confidence

The article is a product/marketing platform launch with qualitative strategy language, not guidance, funding, or regulatory developments.

Market effects

Highlights ongoing consumer-health DTC investment and brand segmentation beyond CBD, which may be a modest read-through for small hemp-adjacent peers.

No specific regional market linkage beyond the company’s San Diego base.

Primarily US-focused DTC branding; no international regulatory or distribution changes mentioned.

Counterpoint

Without disclosed traction metrics, the launch could be more promotional than revenue-driving, limiting any sustained stock reaction.

Key entities

  • CV Sciences, Inc.

    OTCQB-listed consumer health company launching PlusHLTH.com as the DTC hub for its +PlusHLTH line.

  • PlusHLTH.com

    New direct-to-consumer website dedicated exclusively to the +PlusHLTH product line and education content.

  • +PlusHLTH

    Non-cannabinoid nutritional product line including dietary supplements and Empowr plant-based protein with creatine.

Related articles

$CVSIMed

CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex

$CVSIMed

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ext

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$UALMed

United Airlines system outage disrupts departures, 418 flights delayed

United Airlines experienced a system outage causing 418 flight delays. The issue affected departing flights and pilot applications, but not in-air flights or United Express services. The airline resolved the outage, attributing it to a technology issue, not cybersecurity. Recent U.S. tech disruptions include JPMorgan Chase's banking service delays and an FAA air traffic control system malfunction.